What does WE-PHARMA do?

WE-PHARMA is a pharmacy in Huy. Private Limited, started on 26 February 2009, 1 establishment.

What is the address of WE-PHARMA?

The registered office of WE-PHARMA is located at Rue Sous-le-Château 51, 4500 Huy.

Is WE-PHARMA still active?

Yes. According to the CBE (18 September 2026) WE-PHARMA is active, legal situation “Normale toestand”, started on 26 February 2009.

Is WE-PHARMA registered on Peppol?

Yes, WE-PHARMA is registered on the Peppol network with ID 0208:0810070556.

What is the enterprise number of WE-PHARMA?

The enterprise number of WE-PHARMA is BE0810070556.

When was WE-PHARMA founded?

WE-PHARMA was founded on 26 February 2009.

The shares are held by SAGAFIL (88.4%) and AFKIR HAFIDA (1.8%).

Is WE-PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 26 February 2009; 4 annual accounts filed, latest fiscal year 2024.

How much profit did WE-PHARMA make in 2024?

WE-PHARMA posted a profit after taxes of € 4,235 in financial year 2024.

What is the revenue of WE-PHARMA?

In its most recent annual accounts (2024), WE-PHARMA reported revenue of € 2,344,618.

How much does an employee at WE-PHARMA earn?

The average wage cost per full-time employee at WE-PHARMA was € 51,600 in 2024: staff costs of € 769,515 for 14.9 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does WE-PHARMA have?

According to the 2024 annual accounts, WE-PHARMA has 14.9 full-time equivalents (FTE).

WE-PHARMA (Private Limited) - Huy - BE0810070556

Dossier WE-PHARMA, printed on 18 September 2026 from databakkes.be/en/0810070556/we-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2024

WE-PHARMA from Huy, company number BE0810070556, closed financial year 2024 with a result of € 4,235 after tax. For that financial year WE-PHARMA recorded revenue of € 2.3 million and equity of € 1.3 million. Compared with financial year 2023, the result moved from € 9,342 to € 4,235. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 7, 2025.

What it is worth Growing

€ 1.3 million

▲ € 1.1 million vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 4,235

▼ 55% vs 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 15,489

▼ 82% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2024. Retained profit grew to € 103,763.

People and assets in 2024

Full-time equivalents

14.9

▼ 504,387.8 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 769,515

▲ 53% vs 2023

€ 51,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 651,747

Book value of vehicles, furniture and equipment.

Debts at end 2024

Bank debt ≈ 4 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.6 million

▲ 19% vs 2023

€ 140,736 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.

Owed to suppliers

€ 72,263

▼ 60% vs 2023

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 125,091

▲ € 112,116 vs 2023

Taxes, VAT and social contributions still to pay.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	2024	Change 2023 → 2024
Revenue	-	-	-	€ 2,344,618 Revenue 2024: € 2,344,618 First fiscal year in the series
Gross margin	€ 255,639 Gross margin 2021: € 255,639 First fiscal year in the series	€ 525,179 Gross margin 2022: € 525,179 ▲ 105% vs 2021 (€ 255,639) Favourable step	€ 567,247 Gross margin 2023: € 567,247 ▲ 8% vs 2022 (€ 525,179) Favourable step	€ 1,277,623 Gross margin 2024: € 1,277,623 ▲ 125% vs 2023 (€ 567,247) Favourable step	▲ 125%
Profit after taxes	€ 26,143 Profit after taxes 2021: € 26,143 First fiscal year in the series	€ 21,740 Profit after taxes 2022: € 21,740 ▼ 17% vs 2021 (€ 26,143) Unfavourable step	€ 9,342 Profit after taxes 2023: € 9,342 ▼ 57% vs 2022 (€ 21,740) Unfavourable step	€ 4,235 Profit after taxes 2024: € 4,235 ▼ 55% vs 2023 (€ 9,342) Unfavourable step	▼ 55%
Equity	€ 110,646 Equity 2021: € 110,646 First fiscal year in the series	€ 132,386 Equity 2022: € 132,386 ▲ 20% vs 2021 (€ 110,646) Favourable step	€ 141,728 Equity 2023: € 141,728 ▲ 7% vs 2022 (€ 132,386) Favourable step	€ 1,275,963 Equity 2024: € 1,275,963 ▲ € 1.1 million vs 2023 (€ 141,728) Favourable step	▲ € 1.1 million
Total debts	€ 1,150,120 Total debts 2021: € 1,150,120 First fiscal year in the series	€ 1,528,481 Total debts 2022: € 1,528,481 ▲ 33% vs 2021 (€ 1,150,120) Unfavourable step	€ 1,911,132 Total debts 2023: € 1,911,132 ▲ 25% vs 2022 (€ 1,528,481) Unfavourable step	€ 2,190,540 Total debts 2024: € 2,190,540 ▲ 15% vs 2023 (€ 1,911,132) Unfavourable step	▲ 15%
Cash	€ 90,354 Cash 2021: € 90,354 First fiscal year in the series	€ 56,982 Cash 2022: € 56,982 ▼ 37% vs 2021 (€ 90,354) Unfavourable step	€ 85,357 Cash 2023: € 85,357 ▲ 50% vs 2022 (€ 56,982) Favourable step	€ 15,489 Cash 2024: € 15,489 ▼ 82% vs 2023 (€ 85,357) Unfavourable step	▼ 82%
Land & buildings	€ 237,290 Land & buildings 2021: € 237,290 First fiscal year in the series	€ 220,870 Land & buildings 2022: € 220,870 ▼ 7% vs 2021 (€ 237,290) Unchanged	€ 214,195 Land & buildings 2023: € 214,195 ▼ 3% vs 2022 (€ 220,870) Unchanged	€ 456,289 Land & buildings 2024: € 456,289 ▲ 113% vs 2023 (€ 214,195) Unchanged	▲ 113%
Retained profit	€ 68,446 Retained profit 2021: € 68,446 First fiscal year in the series	€ 90,186 Retained profit 2022: € 90,186 ▲ 32% vs 2021 (€ 68,446) Favourable step	€ 99,528 Retained profit 2023: € 99,528 ▲ 10% vs 2022 (€ 90,186) Favourable step	€ 103,763 Retained profit 2024: € 103,763 ▲ 4% vs 2023 (€ 99,528) Favourable step	▲ 4%
Bank debt	€ 653,495 Bank debt 2021: € 653,495 First fiscal year in the series	€ 1,068,751 Bank debt 2022: € 1,068,751 ▲ 64% vs 2021 (€ 653,495) Unfavourable step	€ 1,360,905 Bank debt 2023: € 1,360,905 ▲ 27% vs 2022 (€ 1,068,751) Unfavourable step	€ 1,624,281 Bank debt 2024: € 1,624,281 ▲ 19% vs 2023 (€ 1,360,905) Unfavourable step	▲ 19%
Balance sheet total	€ 1,260,766 Balance sheet total 2021: € 1,260,766 First fiscal year in the series	€ 1,660,867 Balance sheet total 2022: € 1,660,867 ▲ 32% vs 2021 (€ 1,260,766) Unchanged	€ 2,052,860 Balance sheet total 2023: € 2,052,860 ▲ 24% vs 2022 (€ 1,660,867) Unchanged	€ 3,466,502 Balance sheet total 2024: € 3,466,502 ▲ 69% vs 2023 (€ 2,052,860) Unchanged	▲ 69%
Employees (FTE)	-	-	504,402.7 Employees (FTE) 2023: 504,402.7 First fiscal year in the series	14.9 Employees (FTE) 2024: 14.9 ▼ 504,387.8 vs 2023 (504,402.7) Unchanged	▼ 504,387.8

Key figures of WE-PHARMA, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.

What happened to WE-PHARMA?

What happened at WE-PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 7, 2025 New annual accounts for financial year 2024: profit of € 4,235 (▼ 55% vs 2023). Source: NBB ↗
Feb 26, 2009 New establishment in Huy. KBO
Feb 26, 2009 Start of the company according to the CBE. KBO

In short

From € 26,143 profit in 2021 to € 4,235 profit in 2024.

Paid € 44,200 in corporate taxes since 2021.

Best year ever: 2021, with € 26,143 profit.

On average € 85,700 of value added per employee in 2024.

Original PDFs at the National Bank ↗

A new publication or filing at WE-PHARMA? We notify you, reason included.

Follow WE-PHARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Establishments

Establishment units

Physical locations of this company

Registered office

Rue Sous-le-Château 51

4500 Huy

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0810.070.556

VAT number

BE 0810.070.556

Registered office

Rue Sous-le-Château 51, 4500 Huy

Names & denominations

WE-PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

26 February 2009

Peppol

Active · Active since 23 Dec 2025

Activities · NACE

Detailhandel in farmaceutische producten

Activiteiten van verpakkingsbedrijven

View on CBE Public ↗ Annual accounts (NBB) ↗